BioSpace

Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop

Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.

By BioSpace

1 min read
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights